
    
      Patients with stage IV NSCLC will be randomized in a 1:1 ratio to 2 treatment arms
      (durvalumab or SOC therapy). The dual primary objectives of this study are to assess the
      efficacy of durvalumab versus SoC in terms of OS (Overall Survival) in all randomized
      patients and in patients who are at low risk of EM (early mortality)
    
  